Press Releases

November 10, 2022

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

November 2, 2022

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

July 18, 2022

ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors

June 30, 2022

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

Reveal more

In the news

November 11, 2022

New frontier in biology: harnessing the power of the repeatome with Dennis Zaller  |  Biotech2050 podcast

October 7, 2022

ROME CEO Rosana Kapeller Named to Forbes "50 Over 50"  |  Forbes

Reveal more

Publications and presentations

November 14, 2022

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses | American College of Rheumatology Convergence 2022

June 30, 2022

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition  |  PNAS

Reveal more